Guerbet S. A. (GBT) - Total Liabilities
Based on the latest financial reports, Guerbet S. A. (GBT) has total liabilities worth €644.94 Million EUR (≈ $754.00 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Guerbet S. A. cash flow conversion to assess how effectively this company generates cash.
Guerbet S. A. - Total Liabilities Trend (2004–2024)
This chart illustrates how Guerbet S. A.'s total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Guerbet S. A. to evaluate the company's liquid asset resilience ratio.
Guerbet S. A. Competitors by Total Liabilities
The table below lists competitors of Guerbet S. A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bluerock Acquisition Corp. Class A Ordinary Shares
NASDAQ:BLRK
|
USA | $596.17K |
|
Ekovest Bhd
KLSE:8877
|
Malaysia | RM8.28 Billion |
|
Silicon Power Computer & Communications
TWO:4973
|
Taiwan | NT$1.00 Billion |
|
BV Financial, Inc. Common Stock
NASDAQ:BVFL
|
USA | $728.41 Million |
|
Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENS
|
USA | $60.14 Million |
|
Taokaenoi Food & Marketing Public Company Limited
BK:TKN
|
Thailand | ฿1.92 Billion |
|
United Security Bancshares
NASDAQ:UBFO
|
USA | $1.11 Billion |
|
DNF Co.Ltd
KQ:092070
|
Korea | ₩8.13 Billion |
Liability Composition Analysis (2004–2024)
This chart breaks down Guerbet S. A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GBT market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.71 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.63 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guerbet S. A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guerbet S. A. (2004–2024)
The table below shows the annual total liabilities of Guerbet S. A. from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €645.68 Million ≈ $754.87 Million |
-0.20% |
| 2023-12-31 | €646.97 Million ≈ $756.38 Million |
+15.52% |
| 2022-12-31 | €560.07 Million ≈ $654.78 Million |
-5.99% |
| 2021-12-31 | €595.74 Million ≈ $696.48 Million |
+3.08% |
| 2020-12-31 | €577.95 Million ≈ $675.69 Million |
-6.73% |
| 2019-12-31 | €619.68 Million ≈ $724.47 Million |
-13.22% |
| 2018-12-31 | €714.05 Million ≈ $834.80 Million |
+16.78% |
| 2017-12-31 | €611.45 Million ≈ $714.85 Million |
-14.28% |
| 2016-12-31 | €713.35 Million ≈ $833.98 Million |
+15.05% |
| 2015-12-31 | €620.06 Million ≈ $724.91 Million |
+186.36% |
| 2014-12-31 | €216.53 Million ≈ $253.15 Million |
-2.15% |
| 2013-12-31 | €221.29 Million ≈ $258.72 Million |
-5.73% |
| 2012-12-31 | €234.76 Million ≈ $274.46 Million |
-0.07% |
| 2011-12-31 | €234.92 Million ≈ $274.65 Million |
+11.08% |
| 2010-12-31 | €211.49 Million ≈ $247.26 Million |
+11.89% |
| 2009-12-31 | €189.01 Million ≈ $220.98 Million |
-4.17% |
| 2008-12-31 | €197.23 Million ≈ $230.58 Million |
+5.89% |
| 2007-12-31 | €186.26 Million ≈ $217.75 Million |
+6.81% |
| 2006-12-31 | €174.37 Million ≈ $203.86 Million |
+12.75% |
| 2005-12-31 | €154.65 Million ≈ $180.81 Million |
+14.17% |
| 2004-12-31 | €135.46 Million ≈ $158.37 Million |
-- |
About Guerbet S. A.
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solut… Read more